About the Authors
- Beenish Ali
-
Roles Methodology, Writing – original draft
Affiliation Department of Pharmacy, Abasyn University, Peshawar, Pakistan
- Amjad Khan
-
Roles Conceptualization, Methodology, Supervision, Writing – review & editing
* E-mail: dr.amjad@kust.edu.pk
Affiliation Department of Pharmacy, Kohat University of Science and Technology (KUST), Kohat, Pakistan
- Hamad S. Alyami
-
Roles Formal analysis, Funding acquisition
Affiliation Department of Pharmaceutics, Najran University, Najran, Saudi Arabia
- Majeed Ullah
-
Roles Formal analysis, Methodology
Affiliation Department of Pharmacy, Kohat University of Science and Technology (KUST), Kohat, Pakistan
- Abdul Wahab
-
Roles Writing – review & editing
Affiliation Department of Pharmacy, Kohat University of Science and Technology (KUST), Kohat, Pakistan
- Munair Badshah
-
Roles Formal analysis, Writing – review & editing
Affiliation Islam College of Pharmacy, Sialkot, Pakistan
- Attiqa Naz
-
Roles Writing – review & editing
Affiliation Department of Pharmacy, Abasyn University, Peshawar, Pakistan
Competing Interests
The authors of this study have read the journal’s policy, and the authors have the following competing interests to declare: Feorzsons Laboratories Ltd. provided material support in the form of API and facilities. The model drug clopidogrel (Mithri Laboratories Ltd. India; purity 99.81% with reference to USP standard) was obtained from Ferozsons Laboratories Ltd. Nowshera, Pakistan. Excipients used in the study, included tablettose-80 (Molkerei Meggle, Germany), microcrystalline cellulose (F.M.C International, Ireland), primojel {sodium starch glycolate} (F.M.C International, Ire Land), Colloidal silicon dioxide {Aerosil-200} (F.M.C International, Ireland), hydroxylpropyl methylcellulose (Merck KGA, Germany), polyvinyl pyrollidone (I.S.P. Technology, Texas), starch maize (I.C.I, Pakistan) and magnesium stearate (Coin Powder International Company Ltd, Taiwan) were purchased from local market of Peshawar, Pakistan. All the excipients were of pharmaceutical grade and were used as received. This does not affect our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.